Therma Bright Inc. Achieves Key Milestones in Healthcare Innovations

Therma Bright Inc. (OTC: TBRIF), a notable player in the healthcare industry, is advancing its portfolio of innovative medical devices and diagnostic solutions aimed at addressing unmet clinical needs. The company's flagship product, the Venowave VW5, is designed to enhance blood circulation and aims to tap into the deep vein thrombosis (DVT) treatment market, which is projected to reach $1.62 billion by 2032. The Venowave VW5 is an FDA-approved device that improves circulation in the lower extremities through wave-like motions that prevent blood clots, addressing a condition that affects up to 900,000 people in the U.S. annually. The company has secured a nationwide U.S. distribution partner for the Venowave, with a commitment to acquire $2.38 million worth of inventory, and has received a permanent Healthcare Common Procedure Coding System (HCPCS) code from the Centers for Medicare and Medicaid Services (CMS). These milestones bolster Therma Bright's credibility and market positioning in the DVT treatment sector.

Therma Bright is also venturing into the coronary stents market, which was estimated to be $8.82 billion in 2022 and is expected to grow to $16.14 billion by 2030. The company has invested in Inretio, the developer of the Preva® clot-retrieval device, aimed at revolutionizing ischemic stroke treatment. The Preva® device, which recently completed its third successful human trial, promises to improve effectiveness and reduce complications during thrombectomy procedures, potentially benefiting more than 690,000 ischemic stroke patients in the U.S. annually.

In the respiratory disease management sector, Therma Bright holds a stake in InStatin, a company developing inhaled statin therapies for asthma and chronic obstructive pulmonary disease (COPD). With the COPD market estimated to be worth over $16 billion annually, inhaled statin therapies could offer a more effective treatment option for millions of people worldwide. Therma Bright has expanded its investment in InStatin, signaling its confidence in the company's growth trajectory.

Therma Bright's innovation pipeline includes a Digital Cough Test app developed with AI4LYF, which uses AI to monitor respiratory diseases, and other products like the Benepod™ Hot & Cold Contrast Therapy Device, the AcuVid™ COVID-19 Rapid Antigen Test, InterceptCS™ for cold sore prevention, and TherOZap™ for insect bite relief.

With the DVT market expected to reach $1.5 billion by 2032 and other innovations targeting multi-billion-dollar markets, Therma Bright is well-positioned to capture significant market shares. Investors may want to watch this company, whose stock has rallied over 350% this year, as it expands its presence in lucrative healthcare sectors.